Showing 1751-1760 of 5771 results for "".
- Kala Pharmaceuticals Announces Eysuvis Now Covered on UnitedHealthcare Commercial and Cigna Medicarehttps://modernod.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-on-unitedhealthcare-commercial-and-cigna-medicare/2480681/Kala Pharmaceuticals announced that UnitedHealthcare, one of the largest commercial health care plans in the United States covering approximately 13 million people, has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies eff
- Prevent Blindness to Hold 17th Annual “Eyes on Capitol Hill” Advocacy Eventhttps://modernod.com/news/prevent-blindness-to-hold-17th-annual-eyes-on-capitol-hill-advocacy-event/2480666/Prevent Blindness will be holding its 17th annual Eyes on Capitol Hill advocacy day as a virtual event on March 1-2, 2022. Continuing its mission as a patient advocacy group, Prevent Blindness created the Eyes on Capitol Hill program specifically to provide patients, caregivers, al
- Spark Therapeutics Announces Departure of CEO and Founder Jeff Marrazzo; COO Ron Philip Named as Successorhttps://modernod.com/news/spark-therapeutics-announces-departure-of-ceo-and-founder-jeff-marrazzo-coo-ron-philip-named-as-successor/2480664/Spark Therapeutics, a member of the Roche Group, announced that Ron Philip, Spark’s chief operating officer, will succeed co-founder Jeffrey D. Marrazzo as chief executive officer. Mr. Marrazzo, who co-founded the company in 2013, will step down on April 1. “When I thin
- Allergan to Present Data From Durysta and Xen Gel Stent at the 2022 American Glaucoma Society (AGS) Annual Meetinghttps://modernod.com/news/allergan-to-present-data-from-durysta-and-xen-gel-stent-at-the-2022-american-glaucoma-society-ags-annual-meeting/2480663/Allergan announced new data to be presented from it
- 1-800 Contacts Announces New Company Focused on B2B Vision Technologies and Serviceshttps://modernod.com/news/1-800-contacts-announces-new-company-focused-on-b2b-vision-technologies-and-services/2480662/1-800 Contacts recently announced the formation of a standalone business, Luna Solutions, focused on providing technology and services to third parties in the vision space. The company offers 20 integrated technologies and services–ranging from telehealth platforms for n
- TearSolutions Meets with FDA and Announces Next Steps in the Development of Lacripephttps://modernod.com/news/tearsolutions-meets-with-fda-and-announces-next-steps-in-the-development-of-lacripep/2480661/TearSolutions, the developer of a replacement therapy for the treatment of dry eye disease (DED) called Lacripep, announced that in late 2021 it received official minutes from a Type C meeting with the FDA regarding the development of Lacripep for the treatment of DED and is planni
- Oyster Point Pharma Announces Tyrvaya Nasal Spray Now Covered by Express Scriptshttps://modernod.com/news/oyster-point-pharma-announces-tyrvaya-nasal-spray-now-covered-by-express-scripts/2480656/Oyster Point Pharma announced Tyrvaya Nasal Spray’s placement on the Express Scripts National Preferred, Basic, and High Performance Formularies, which collectively covers an estimated 26 million people, effective February 19, 2022. Tyrvaya is the first and only na
- FCI Ophthalmics Announces FDA Clearance of Oculid Implantable and External Eyelid Weights for the Treatment of Lagophthalmoshttps://modernod.com/news/fci-ophthalmics-announces-fda-clearance-of-oculid-implantable-and-external-eyelid-weights-for-the-treatment-of-lagophthalmos/2480641/FCI Ophthalmics announced <
- Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura in Patients with GAhttps://modernod.com/news/iveric-bio-announces-foveal-anatomy-post-hoc-analysis-from-gather1-clinical-trial-of-zimura-in-patients-with-ga/2480635/Iveric bio announced a post-hoc analysis which evaluated various geographic atrophy (GA) growth parameters to explore the rate of disease progression within various regions in the fovea in a subset of patients from the GATHER1 Zimura (avacincaptad pegol) phase 3 clinical trial for the treatm
- Waldo Announces the Acquisition of Placid0, Maker of Eye Assessment Apphttps://modernod.com/news/waldo-announces-the-acquisition-of-placid0/2480632/Waldo announces the acquisition of Placid0, maker of EASY, an eye assessment system mobile application. Financial terms of the deal were not disclosed. The acquisition is the next step in Waldo’s movement to make eye care an essential part of everyday life, with bo